Evommune (EVMN) Operating Leases (2025 - 2026)

Evommune (EVMN) posted quarterly Operating Leases of $6.8 million for Q1 2026, up 424.65% quarter-over-quarter from $1.3 million in Q4 2025.

Evommune (EVMN) Operating Leases (2025 - 2026) Analysis & Trends

Evommune (EVMN) has reported Operating Leases for 2 consecutive years, with $6.8 million the latest figure, recorded in Q1 2026.

In Q1 2026, Operating Leases changed N/A year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $6.8 million (changed N/A YoY), while the FY2025 annual figure was $1.3 million, changed N/A from the prior year.
Operating Leases grew to $6.8 million in Q1 2026 per EVMN's latest filing, from $1.3 million in the prior quarter.
Across five years, Operating Leases topped out at $6.8 million in Q1 2026 and bottomed at $1.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Evommune	531.53 Mn	330.73 Mn	-

Download Data